Wenxi Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wenxi Huang has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Jingchuan Guo
Department of Pharmacy Practice, Purdue University College of Pharmacy, Indianapolis, USA
4 shared publications - Jiang Bian
Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN, USA
3 shared publications Jiang Bian
Department of Biostatistics and Health Data Science Indiana University School of Medicine Indianapolis Indiana USA
2 shared publications- Rotana M. Radwan
Department of Pharmacy Practice, Purdue University College of Pharmacy, Indianapolis, USA
2 shared publications - Yi Guo
Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, USA
2 shared publications Angela Marija Pecoski
Department of Pharmacy Practice, College of Pharmacy Purdue University Indianapolis Indiana USA
1 shared publication
Latest Publications
- Open Access
- 14 November 2026
- Published by Springer Nature in npj Digital Medicine
Learning health system frameworks and the integration of artificial intelligence and data science in United States health care: a scoping review
- 14 November 2026
- Published by Springer Nature in npj Digital Medicine
Open AccessLearning health system frameworks and the integration of artificial intelligence and data science in United States health care: a scoping review
- 17 September 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (12) , 11475-11484
Real‐World Adherence Trajectories of GLP ‐1 Receptor Agonists Among Adults and Paediatric Patients With Obesity
Aims: Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are increasingly used for obesity treatment, but real‐world adherence patterns, particularly among individuals without diabetes and paediatric patients, remain poorly characterised. We aimed to identify 12‐month GLP‐1 RA adherence trajectories among adults and paediatric patients with obesity without diabetes and to evaluate factors associated with adherence. Materials and Methods: We conducted a retrospective cohort study using 2021–2023 MarketScan commercial claims data. Individuals aged ≥ 10 years with obesity without diabetes who initiated GLP‐1 RAs were included. Adherence was measured as monthly proportion of days covered (PDC) over 12 months. Group‐based trajectory modelling was conducted separately in adult and paediatric cohorts. Multivariable logistic regression was used to identify factors associated with membership in the persistent‐user trajectory. Results: The study included 201 229 adults and 1139 paediatric patients. Five adherence trajectories were identified in each cohort. Among adults, trajectories included immediate discontinuers (19.6%), early discontinuers (23.5%), late discontinuers (20.7%), intermittent adherents (5.5%) and persistent users (30.7%), with mean annual PDC ranging from 0.10 to 0.87. Paediatric trajectory groups were more evenly distributed, with each group representing approximately 18%–22% of the cohort and persistent users comprising 20.3%. Geographic region was consistently associated with adherence, with higher odds of persistent use in the Northeast versus the South among adults (odds ratio [OR], 1.32) and paediatric patients (OR, 1.65). Conclusions: Most adults and paediatric patients with obesity had suboptimal adherence to GLP‐1 RA use over 12 months. Distinct adherence trajectories and consistent regional differences highlight opportunities to better understand and address barriers to long‐term obesity pharmacotherapy.
- 17 September 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (12) , 11475-11484
Real‐World Adherence Trajectories of GLP ‐1 Receptor Agonists Among Adults and Paediatric Patients With Obesity
Aims: Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are increasingly used for obesity treatment, but real‐world adherence patterns, particularly among individuals without diabetes and paediatric patients, remain poorly characterised. We aimed to identify 12‐month GLP‐1 RA adherence trajectories among adults and paediatric patients with obesity without diabetes and to evaluate factors associated with adherence. Materials and Methods: We conducted a retrospective cohort study using 2021–2023 MarketScan commercial claims data. Individuals aged ≥ 10 years with obesity without diabetes who initiated GLP‐1 RAs were included. Adherence was measured as monthly proportion of days covered (PDC) over 12 months. Group‐based trajectory modelling was conducted separately in adult and paediatric cohorts. Multivariable logistic regression was used to identify factors associated with membership in the persistent‐user trajectory. Results: The study included 201 229 adults and 1139 paediatric patients. Five adherence trajectories were identified in each cohort. Among adults, trajectories included immediate discontinuers (19.6%), early discontinuers (23.5%), late discontinuers (20.7%), intermittent adherents (5.5%) and persistent users (30.7%), with mean annual PDC ranging from 0.10 to 0.87. Paediatric trajectory groups were more evenly distributed, with each group representing approximately 18%–22% of the cohort and persistent users comprising 20.3%. Geographic region was consistently associated with adherence, with higher odds of persistent use in the Northeast versus the South among adults (odds ratio [OR], 1.32) and paediatric patients (OR, 1.65). Conclusions: Most adults and paediatric patients with obesity had suboptimal adherence to GLP‐1 RA use over 12 months. Distinct adherence trajectories and consistent regional differences highlight opportunities to better understand and address barriers to long‐term obesity pharmacotherapy.
- 5 March 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (5) , 1114
Correction to: Race- and Ethnicity-Related Disparities in Predialysis Nephrology Care, Kidney Disease Education, and Home Dialysis Utilization
An abstract is unavailable. This article is available as a PDF only.
- 5 March 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (5) , 1114
Correction to: Race- and Ethnicity-Related Disparities in Predialysis Nephrology Care, Kidney Disease Education, and Home Dialysis Utilization
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 25 August 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9 (1) , e71595
External Exposome Factors and Adverse Heart Failure Outcomes in the OneFlorida+ Network: Retrospective Cohort Study
Background: Heart failure (HF) readmission rates vary across geographic regions in the United States, yet the impact of external exposome factors, such as contextual-level social determinants of health (SDoH), on adverse HF outcomes is not well understood. Objective: This study aims to examine the association between external exposome factors and the risk of HF readmission and all-cause mortality using a data-driven approach. Methods: We conducted a retrospective cohort study using electronic health record (EHR) data from the OneFlorida+ Network, including patients hospitalized for HF (HHF) from 2016 to 2022. A total of 1308 external exposome factors, covering a wide range of SDoH (eg, economic stability, education, health care access, natural and built environments, and social context), were linked to patients’ EHR data based on their county-level residential location. Patients were followed for 1 year after their first HHF to capture readmission and mortality events. We applied the least absolute shrinkage and selection operator regularization to preselect candidate variables, followed by a 2-phase external exposome-wide association study using mixed-effects logistic regression to identify key factors associated with the composite outcome of 1-year HF readmission and mortality. Results: Among 63,940 patients with HF (n=30,475, 48% women; mean age 65, SD 14 years), higher maximum temperature in May was significantly associated with increased risk of the composite outcome (adjusted odds ratio [aOR] 1.04, 95% CI 1.02-1.06; P<.001). Subgroup analyses showed consistent associations across age, sex, race, socioeconomic status, and rural or urban strata. Conclusions: Using a data-driven approach, we found that elevated maximum temperature in May (late spring) was significantly associated with HF readmission and mortality in Florida. Further investigations are warranted to uncover the intricate mechanisms through which extreme heat potentially influences HF outcomes.
- 25 August 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9 (1) , e71595
Open AccessExternal Exposome Factors and Adverse Heart Failure Outcomes in the OneFlorida+ Network: Retrospective Cohort Study
Background: Heart failure (HF) readmission rates vary across geographic regions in the United States, yet the impact of external exposome factors, such as contextual-level social determinants of health (SDoH), on adverse HF outcomes is not well understood. Objective: This study aims to examine the association between external exposome factors and the risk of HF readmission and all-cause mortality using a data-driven approach. Methods: We conducted a retrospective cohort study using electronic health record (EHR) data from the OneFlorida+ Network, including patients hospitalized for HF (HHF) from 2016 to 2022. A total of 1308 external exposome factors, covering a wide range of SDoH (eg, economic stability, education, health care access, natural and built environments, and social context), were linked to patients’ EHR data based on their county-level residential location. Patients were followed for 1 year after their first HHF to capture readmission and mortality events. We applied the least absolute shrinkage and selection operator regularization to preselect candidate variables, followed by a 2-phase external exposome-wide association study using mixed-effects logistic regression to identify key factors associated with the composite outcome of 1-year HF readmission and mortality. Results: Among 63,940 patients with HF (n=30,475, 48% women; mean age 65, SD 14 years), higher maximum temperature in May was significantly associated with increased risk of the composite outcome (adjusted odds ratio [aOR] 1.04, 95% CI 1.02-1.06; P<.001). Subgroup analyses showed consistent associations across age, sex, race, socioeconomic status, and rural or urban strata. Conclusions: Using a data-driven approach, we found that elevated maximum temperature in May (late spring) was significantly associated with HF readmission and mortality in Florida. Further investigations are warranted to uncover the intricate mechanisms through which extreme heat potentially influences HF outcomes.
- 17 June 2025
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 45 (7) , 426-434
Heterogeneous effects of sodium–glucose cotransporter‐2 inhibitors compared to dipeptidyl peptidase‐4 inhibitors on nephrolithiasis in older adults with type 2 diabetes
Background: Type 2 diabetes (T2D) is associated with an increased risk of nephrolithiasis. Emerging evidence suggests that sodium–glucose cotransporter 2 inhibitors (SGLT2i) may reduce this risk; however, data remain inconclusive. Objective: To examine the risk of nephrolithiasis among users of SGLT2i compared to dipeptidyl peptidase‐4 inhibitors (DPP4i) in a real‐world population of older adults with T2D. Methods: A retrospective cohort study was conducted using claims data from a sample of national Medicare beneficiaries. Individuals with T2D who initiated SGLT2i or DPP4i therapy between January 1, 2016, and December 31, 2018, were identified. The index date was defined as the date of the first prescription for either SGLT2i or DPP4i, with no prior use of either drug in the preceding year. Patients were followed from the index date until the earliest occurrence of a medical encounter with a primary diagnosis of nephrolithiasis, death, or December 31, 2018. Inverse probability of treatment weighting (IPTW) was used to balance baseline covariates, including sociodemographic characteristics, comorbidities, and comedication use. Cox proportional hazards regression models were applied to compare the risk of nephrolithiasis between SGLT2i and DPP4i users. Additional analyses were conducted within subgroups defined by sex, race, and baseline nephrolithiasis status. Results: Of 116,506 included Medicare beneficiaries with T2D (mean age 72 ± 10 years, 53% women), 0.96% developed nephrolithiasis over a median follow‐up of 360 days (interquartile range [IQR] 200–467 days). The incidence rate of nephrolithiasis was 9.89 (95% confidence interval [CI] 8.49–11.52) and 11.02 (95% CI 10.34–11.73) events per 1000 person‐years in the SGLT2i and DPP4i groups, respectively. After applying IPTW, baseline characteristics were well balanced between the two groups. SGLT2i use was associated with a significantly lower risk of nephrolithiasis compared to DPP4i use (hazard ratio [HR], 0.81; 95% CI 0.66–0.99; p = 0.04). In subgroup analyses, SGLT2i use compared to DPP4i was associated with a significantly lower risk of nephrolithiasis among males (HR 0.75; 95% CI 0.58–0.98; p = 0.04), non‐Hispanic Black (NHB) individuals (HR 0.22; 95% CI 0.07–0.64; p < 0.01), and those without baseline nephrolithiasis (HR 0.68; 95% CI 0.53–0.88; p < 0.01). Conclusions: In older adults with T2D, SGLT2i use was associated with a lower risk of nephrolithiasis compared to DPP4i, particularly among men, NHB individuals, and those without baseline nephrolithiasis. Although causality cannot be established, these findings provide real‐world evidence supporting a potential benefit of SGLT2is in reducing nephrolithiasis risk, offering valuable insights to guide the selection of glucose‐lowering drugs in older adults with T2D.
- 17 June 2025
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 45 (7) , 426-434
Heterogeneous effects of sodium–glucose cotransporter‐2 inhibitors compared to dipeptidyl peptidase‐4 inhibitors on nephrolithiasis in older adults with type 2 diabetes
Background: Type 2 diabetes (T2D) is associated with an increased risk of nephrolithiasis. Emerging evidence suggests that sodium–glucose cotransporter 2 inhibitors (SGLT2i) may reduce this risk; however, data remain inconclusive. Objective: To examine the risk of nephrolithiasis among users of SGLT2i compared to dipeptidyl peptidase‐4 inhibitors (DPP4i) in a real‐world population of older adults with T2D. Methods: A retrospective cohort study was conducted using claims data from a sample of national Medicare beneficiaries. Individuals with T2D who initiated SGLT2i or DPP4i therapy between January 1, 2016, and December 31, 2018, were identified. The index date was defined as the date of the first prescription for either SGLT2i or DPP4i, with no prior use of either drug in the preceding year. Patients were followed from the index date until the earliest occurrence of a medical encounter with a primary diagnosis of nephrolithiasis, death, or December 31, 2018. Inverse probability of treatment weighting (IPTW) was used to balance baseline covariates, including sociodemographic characteristics, comorbidities, and comedication use. Cox proportional hazards regression models were applied to compare the risk of nephrolithiasis between SGLT2i and DPP4i users. Additional analyses were conducted within subgroups defined by sex, race, and baseline nephrolithiasis status. Results: Of 116,506 included Medicare beneficiaries with T2D (mean age 72 ± 10 years, 53% women), 0.96% developed nephrolithiasis over a median follow‐up of 360 days (interquartile range [IQR] 200–467 days). The incidence rate of nephrolithiasis was 9.89 (95% confidence interval [CI] 8.49–11.52) and 11.02 (95% CI 10.34–11.73) events per 1000 person‐years in the SGLT2i and DPP4i groups, respectively. After applying IPTW, baseline characteristics were well balanced between the two groups. SGLT2i use was associated with a significantly lower risk of nephrolithiasis compared to DPP4i use (hazard ratio [HR], 0.81; 95% CI 0.66–0.99; p = 0.04). In subgroup analyses, SGLT2i use compared to DPP4i was associated with a significantly lower risk of nephrolithiasis among males (HR 0.75; 95% CI 0.58–0.98; p = 0.04), non‐Hispanic Black (NHB) individuals (HR 0.22; 95% CI 0.07–0.64; p < 0.01), and those without baseline nephrolithiasis (HR 0.68; 95% CI 0.53–0.88; p < 0.01). Conclusions: In older adults with T2D, SGLT2i use was associated with a lower risk of nephrolithiasis compared to DPP4i, particularly among men, NHB individuals, and those without baseline nephrolithiasis. Although causality cannot be established, these findings provide real‐world evidence supporting a potential benefit of SGLT2is in reducing nephrolithiasis risk, offering valuable insights to guide the selection of glucose‐lowering drugs in older adults with T2D.
- 1 March 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 498 (1) , 186-192
Steady-state structural fluctuation is a predictor of the necessity of pausing-mediated co-translational folding for small proteins
- 1 March 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 498 (1) , 186-192
Steady-state structural fluctuation is a predictor of the necessity of pausing-mediated co-translational folding for small proteins
- Open Access
- 13 November 2017
- Published by Florida International University
Characterizing the Molecular Structure and Reactivity of Natural Organic Matter in The Everglades
Mangroves are the dominant vegetation in Everglades estuarine environment and are known to contain polyphenols such as tannins, which present similar fluorescence properties as some amino acid fluorophores. In the present study, gas chromatography–mass spectrometry (GC/MS) was used to quantify gallic acid, which is a normal monomer of polyphenols. The quantitative GC/MS analytical method was developed using gallic acid and tannic acid standards to quantify the false ‘protein-like’ fluorescence in DOM. The present study also compared the optical properties, reactive species (RS) production and radical scavenging ability of DOM from different regions of the Everglades and a correlation was observed between DOM composition and its photo-productivity. In general, the reactive species quantum yield decreased with increased DOM redox potential. The RS formation rates were controlled by the DOC and CDOM abundace. Normalized RS formation rates were shown to be influenced by DOM aromaticity and molecular weight characteristics
- 13 November 2017
- Published by Florida International University
Open AccessCharacterizing the Molecular Structure and Reactivity of Natural Organic Matter in The Everglades
Mangroves are the dominant vegetation in Everglades estuarine environment and are known to contain polyphenols such as tannins, which present similar fluorescence properties as some amino acid fluorophores. In the present study, gas chromatography–mass spectrometry (GC/MS) was used to quantify gallic acid, which is a normal monomer of polyphenols. The quantitative GC/MS analytical method was developed using gallic acid and tannic acid standards to quantify the false ‘protein-like’ fluorescence in DOM. The present study also compared the optical properties, reactive species (RS) production and radical scavenging ability of DOM from different regions of the Everglades and a correlation was observed between DOM composition and its photo-productivity. In general, the reactive species quantum yield decreased with increased DOM redox potential. The RS formation rates were controlled by the DOC and CDOM abundace. Normalized RS formation rates were shown to be influenced by DOM aromaticity and molecular weight characteristics